Therini Bio has initiated a Phase 1b trial of THN391, a monoclonal antibody targeting fibrin's inflammatory epitope, in patients with diabetic macular edema. The approach addresses a distinct pathological mechanism—fibrin-driven neuroinflammation—separate from the VEGF inhibition that dominates current treatment paradigms, with initial efficacy and safety data expected in late 2026.
Key Points
- THN391 blocks fibrin's inflammatory signal while preserving normal coagulation function
- Preclinical data show efficacy comparable to VEGF antagonists in controlling retinal leakage
- Dual-mechanism candidate (THN622) combines fibrin and VEGF inhibition for potential synergy
Longevity Analysis
Diabetic macular edema represents a convergence of metabolic dysfunction, vascular compromise, and neuroinflammatory cascade—three mechanisms that accelerate tissue degeneration and visual loss. A therapeutic approach that addresses fibrin's role in perpetuating inflammation, rather than only blocking vascular growth factors, targets an upstream driver of the pathological process. This mechanism matters beyond the eye: fibrin-mediated inflammation participates in vascular cognitive decline and other age-related neurodegenerative conditions. Success in this trial would validate fibrin inhibition as a distinct therapeutic axis and suggest broader applications in preventing or slowing vascular-driven neurodegeneration.
Original published by LT Wire.